Mendus

.Hero-module--bg-image--629a6:before { opacity: 1; background-image: url('/static/64ff3c5dc09358fb1f6e6ee5f4a8dcf4/e65ba/Mendus_woman-with-surfboard_darker-min-compress.jpg'); }

Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.

<picture><source type="image/webp" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/dbb21/disarming-cancer-threat.webp 151w,/static/f6777646b01027295d9a7ee75dea7c96/8cdf4/disarming-cancer-threat.webp 302w,/static/f6777646b01027295d9a7ee75dea7c96/39272/disarming-cancer-threat.webp 603w" sizes="(min-width: 603px) 603px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 603px) 603px, 100vw" decoding="async" loading="lazy" src="/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/bedb7/disarming-cancer-threat.jpg 151w,/static/f6777646b01027295d9a7ee75dea7c96/8f82e/disarming-cancer-threat.jpg 302w,/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg 603w" alt="&lt;p&gt;Middle aged man running in a field of grass, surrounded by mountains.&lt;/p&gt;
"/></picture>
Gaining the 
upper handToday, tumor recurrence causes the vast majority of cancer-related deaths. We want to change this by designing new therapeutic options that tip the balance in favor of the immune system.
What we do

<picture><source type="image/webp" srcSet="/static/aafedabe406814250bbca33ccd38dca0/5b094/ways-to-make-dif.webp 225w,/static/aafedabe406814250bbca33ccd38dca0/ecbb3/ways-to-make-dif.webp 450w,/static/aafedabe406814250bbca33ccd38dca0/10d3d/ways-to-make-dif.webp 900w" sizes="(min-width: 900px) 900px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 900px) 900px, 100vw" decoding="async" loading="lazy" src="/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg" srcSet="/static/aafedabe406814250bbca33ccd38dca0/51892/ways-to-make-dif.jpg 225w,/static/aafedabe406814250bbca33ccd38dca0/ea40c/ways-to-make-dif.jpg 450w,/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg 900w" alt=""/></picture>
New ways to make a differenceWe dare to shine the light of science down new and unexplored paths to improve the course of cancer treatment.
About us

Latest newsAll news
6 December 2023Latest
Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML
Press Release    Stockholm, Sweden, December 6, 2023        CADENCE Phase 2 trial will evaluate vididencel in combination with oral azacitidineRandomized controlled trial in 40 patients, with...
Learn more
5 December 2023
Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6
Press Release    Stockholm, Sweden, December 5, 2023        Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it...
Learn more
4 December 2023
Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023
Press Release      Stockholm, Sweden, December 4, 2023            Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today...
Learn more
17 November 2023
Mendus Announces Nomination Committee for the 2024 Annual General Meeting
Press Release      Stockholm, Sweden, November 17, 2023            Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee have been appointed in accordance with the...
Learn more
13 November 2023
NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)
Press Release        Stockholm, Sweden, November 13, 2023                The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Extraordinary General...
Learn more
9 November 2023
Mendus AB Interim Report January – September 2023
Press Release    Stockholm, Sweden, November 9, 2023        So far in 2023, Mendus has realized significant progress in its corporate development, and we aim to end the year strong    The progress...
Learn more
6 November 2023
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
Press Release          Stockholm, Sweden, November 6, 2023                    Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence,...
Learn more

For investors
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors
<picture><source type="image/webp" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/7bc26/124.webp 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/5e603/124.webp 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/af8c4/124.webp 1656w" sizes="(min-width: 1656px) 1656px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1656px) 1656px, 100vw" decoding="async" loading="lazy" src="/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/1d336/124.jpg 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/8753d/124.jpg 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg 1656w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Latest presentation17 October 2023Corporate Presentation - October 2023
27 June 2023Replay of Vididencel 2023 Update Webcast
17 April 2023Replay Investor Webcast – April 2023
30 March 2023Innate Killer Summit 2023
13 December 2022Replay of ASH 2022 Webcast
30 November 2022Replay of Mendus' KOL Event
Financial calendar17 February 2023Publication of Year-end Report 2022
17 April 2023Publication of Annual Report 2022
12 May 2023Annual General Meeting
12 May 2023Publication of Q1 Report
29 August 2023Publication of Q2 Report
9 November 2023Publication of Q3 Report
14 February 2024Publication of Year-end Report 2023

EventsAll events
29 November 2023
Previous
CEO Erik Manting gives interview to Edison ahead of Mendus’s presentation of updated vididencel survivability data at ASH 2023Learn more
November 2023Previous
Interview with CEO Erik Manting
CEO Erik Manting presents at Redeye Life Science Day 2023 – 23 November 
Learn more
November 2023Previous
Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Mendus will present data from the ongoing Phase 1 ALISON trial in ovarian cancer at SITC 2023. Full abstracts are expected to be published online on Oct. 31, 2023.
Learn more
October 2023Previous
HealthTech Innovation Days
Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present a Company Update at the conference.
Learn more

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--1792894973-5HHgRaR6FS1cQQb8zrsJui:before { opacity: 1; background-image: url('/static/db5cac225ec6b40b3e48015942da980e/d3468/home-section-fullwidth.jpg'); }

A life-changing careerAt Mendus, we share a strong commitment to improve the lives of people with cancer. And we do it as a team who values honesty and togetherness. Join us and help change cancer treatment at its core.
Careers

Changing the course of cancer treatment

Gaining the upper hand

New ways to make a difference

Latest news

Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML

Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6

Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023

Mendus Announces Nomination Committee for the 2024 Annual General Meeting

NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)

Mendus AB Interim Report January – September 2023

Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023

For investors

Invest in future cancer care

Latest presentation

Financial calendar

Events

CEO Erik Manting gives interview to Edison ahead of Mendus’s presentation of updated vididencel survivability data at ASH 2023

Interview with CEO Erik Manting

Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

HealthTech Innovation Days

A life-changing career

Keep up to date

Gaining the
upper hand